Tabari Biomedical Student Research Journal

en HER2 Amplification in Non-Mutant RAS Status in Patients with Metastatic Colorectal Cancer and the 2-Year Survival Rate Hematology and Oncology Research (Original) Introduction: HER2 amplification is a therapeutic target in breast and stomach cancer, but the relationship between HER2 and response to treatment in metastatic colorectal cancer has not been fully determined. This study investigated the incidence of HER2 overexpression in non-mutant RAS patients with metastatic colorectal cancer to determine the two-year survival rate in patients referred to Imam Khomeini Hospital in Sari between 2014-2018. Material and Methods: This cohort study was conducted between 2014 and 2018 among patients with metastatic colorectal cancer who were identified as non-mutant (wild) NRAS, KRAS, and BRAF genes. Patients received cetuximab. The clinical course of the patients was evaluated simultaneously during this evaluation period, and the two-year survival rate of the patients and the response to cetuximab were evaluated. Data were entered into SPSS software version 24 and analyzed. Results: Twenty-five patients were examined, 60% were men. The most common symptom in patients was abdominal pain (32%). The majority (72%) of the study patients did not undergo surgery, 24% underwent hemicolectomy and 4% underwent total colectomy. The incidence of HER2 positive in women was higher than in men (10% vs. 6%) and in grade 1 patients was higher than grade 2 (8.3% vs. 1.1%). Forty-four percents of patients had positive two-year survival. Among patients with positive two-year survival, 9.1% were HER2 positive and 90.9% were HER2 negative. Conclusion: The results of the study showed that infectious causes (influenza) and underlying CLD including asthma were major causes of ARF in pregnant women. Thus, more careful attention is needed to control the underlying disease, and planning for easier access to the influenza vaccine can play an effective role in reducing the incidence of pulmonary infections. Cetuximab, Colorectal Cancer, HER2 1 10 http://tbsrj.mazums.ac.ir/browse.php?a_code=A-10-3560-1&slc_lang=en&sid=1 Ehsan Zaboli paya_1358@yahoo.com 100319475328460031105 100319475328460031105 No Gastrointestinal Cancer Research Center, Non‐Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran Davood Shirazi MajiMiriha dvdshirazi9@gmail.com 100319475328460031106 100319475328460031106 No Department of Internal Medicine, School of Medicine, Shahid Beheshti Hospital, Hamadan University of Medical Sciences, Hamadan, Iran Farshad Naghshvar farshad.naghshvar@yahoo.com 100319475328460031107 100319475328460031107 No Department of Pathology, School of Medicine, Sari Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran Reza Alizadeh-Navaei reza.nava@gmail.com 100319475328460031108 100319475328460031108 No Gastrointestinal Cancer Research Center, Non‐Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran Masumeh Shirazi HajiMiriha dr.masumeh@gmail.com 100319475328460031109 100319475328460031109 Yes Department of Internal Medicine, School of Medicine, Sari Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran